BRIEF published on 05/28/2024 at 13:05, 11 months 2 days ago CureVac Announces Dosing of First Participant in Phase 2 Influenza Study GSK MRNA Technology Phase 2 Study CureVac Influenza Vaccine
BRIEF published on 05/28/2024 at 13:05, 11 months 2 days ago CureVac annonce le dosage du premier participant à l'étude de phase 2 sur la grippe GSK Technologie ARNm Étude De Phase 2 CureVac Vaccin Contre La Grippe
PRESS RELEASE published on 05/28/2024 at 13:00, 11 months 2 days ago CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CureVac initiates Phase 2 study in collaboration with GSK for seasonal influenza vaccine, targeting improved immune responses against influenza B strain GSK Vaccine Development Phase 2 Study CureVac Seasonal Influenza
BRIEF published on 05/23/2024 at 13:05, 11 months 7 days ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Financial Results Business Update Q1 2024 CureVac FDA Fast Track
BRIEF published on 05/23/2024 at 13:05, 11 months 7 days ago CureVac annonce ses résultats financiers pour le premier trimestre 2024 et fait le point sur ses activités Résultats Financiers Mise À Jour De L'entreprise T1 2024 CureVac Procédure Accélérée De La FDA
PRESS RELEASE published on 05/23/2024 at 13:00, 11 months 7 days ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRIEF published on 04/24/2024 at 13:11, 1 year ago CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRIEF published on 04/24/2024 at 13:11, 1 year ago CureVac annonce ses résultats financiers pour 2023 et des mises à jour stratégiques sur ses activités Technologie ARNm CureVac Collaborations Pharmaceutiques Vaccins Contre L'oncologie Vaccins Prophylactiques
BRIEF published on 04/24/2024 at 13:08, 1 year ago CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
BRIEF published on 04/24/2024 at 13:08, 1 year ago CureVac commence une étude combinée de phase 1/2 pour le vaccin contre la grippe aviaire H5N1 avec GSK GSK CureVac Étude De Phase 1/2 Grippe H5N1 Vaccin À ARNm
Published on 04/30/2025 at 17:40, 1 hour 26 minutes ago Sekur Private Data Ltd. Announces Closing of First Tranche of its Non-Brokered Private Placement
Published on 04/30/2025 at 15:30, 3 hours 36 minutes ago Argo Blockchain PLC Announces Financial Update and Listing Suspension Request
Published on 04/30/2025 at 15:30, 3 hours 36 minutes ago Ostrom Climate Reports Audited Year-End 2024 and Fiscal Q4 Financial Statements and Announces Leadership Changes
Published on 04/30/2025 at 15:00, 4 hours 6 minutes ago Kingfisher Announces Addition of Ashwath Mehra to Advisory Board
Published on 04/30/2025 at 14:30, 4 hours 36 minutes ago Trans Canada Gold Corp. to Sell Its 18.75 % Petroleum and Natural Gas Rights and Interest in the Non-performing 8-23-049-1 W4M GP Well Only, and the GP Petroleum Zone Rights Within the AMI to Its Working Interest Partners
Published on 04/30/2025 at 18:52, 13 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/30/2025 at 18:37, 28 minutes ago Funding Circle Holdings plc: TVR-Total Voting Rights
Published on 04/30/2025 at 18:29, 36 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 04/30/2025 at 18:18, 48 minutes ago Annual Report 2024 as of December 31, 2024 for Mercedes-Benz Finance Canada Inc. is now available online
Published on 04/30/2025 at 18:14, 52 minutes ago paragon's robustness confirmed by significant increase in operating result despite decline in sales
Published on 04/30/2025 at 18:55, 10 minutes ago Access to information in respect of the General Shareholders’ Meeting to be held on June 5, 2025
Published on 04/30/2025 at 18:55, 10 minutes ago Mise à disposition des documents relatifs à l'AG du 5 juin 2025
Published on 04/30/2025 at 18:15, 51 minutes ago EURAZEO ACQUIRES THE REMAINING CAPITAL OF KURMA PARTNERS, AN ASSET MANAGEMENT COMPANY SPECIALISING IN MEDICAL INNOVATION AND BIOTECHNOLOGY
Published on 04/30/2025 at 18:15, 51 minutes ago EURAZEO ACQUIERT LE SOLDE DU CAPITAL DE KURMA PARTNERS, SOCIETE DE GESTION SPECIALISTE DE L’INNOVATION MEDICALE ET DES BIOTECHNOLOGIES
